Core Viewpoint - Roche announced a negative opinion from the European Medicines Agency (EMA) regarding the conditional marketing authorization (CMA) application for the Elevidys therapy aimed at treating Duchenne muscular dystrophy (DMD) in patients aged 3 to 7 years [1] Group 1 - Roche plans to continue collaborating with the EMA to explore potential solutions due to the significant unmet medical needs in the DMD field [1]